Steward Partners Investment Advisory’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-15
| Closed | -$8 | – | 4190 |
|
|
2024
Q4 | $8 | Hold |
15
| – | – | ﹤0.01% | 3960 |
|
|
2024
Q3 | $20 | Hold |
15
| – | – | ﹤0.01% | 3715 |
|
|
2024
Q2 | $114 | Hold |
15
| – | – | ﹤0.01% | 3552 |
|
|
2024
Q1 | $135 | Hold |
15
| – | – | ﹤0.01% | 3495 |
|
|
2023
Q4 | $161 | Hold |
15
| – | – | ﹤0.01% | 3421 |
|
|
2023
Q3 | $90 | Hold |
15
| – | – | ﹤0.01% | 3320 |
|
|
2023
Q2 | $104 | Hold |
15
| – | – | ﹤0.01% | 3267 |
|
|
2023
Q1 | $236 | Hold |
15
| – | – | ﹤0.01% | 3220 |
|
|
2022
Q4 | $300 | Hold |
15
| – | – | ﹤0.01% | 3230 |
|
|
2022
Q3 | $0 | Hold |
15
| – | – | ﹤0.01% | 3440 |
|
|
2022
Q2 | $0 | Hold |
15
| – | – | ﹤0.01% | 3422 |
|
|
2022
Q1 | $0 | Hold |
15
| – | – | ﹤0.01% | 3414 |
|
|
2021
Q4 | $1K | Hold |
15
| – | – | ﹤0.01% | 3148 |
|
|
2021
Q3 | $1K | Hold |
15
| – | – | ﹤0.01% | 3119 |
|
|
2021
Q2 | $1K | Sell |
15
-350
| -96% | -$41.5K | ﹤0.01% | 7007 |
|
|
2021
Q1 | $60.7K | Buy |
365
+350
| +2,333% | +$46.3K | ﹤0.01% | 1883 |
|
|
2020
Q4 | $1K | Buy |
+15
| New | +$949 | ﹤0.01% | 2836 |
|
Steward Partners Investment Advisory's ONCT Position: Q1 2025 in Review
Steward Partners Investment Advisory sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2025, closing a stake of 15 shares — an estimated $8 sold.
Steward Partners Investment Advisory first reported a position in ONCT in Q4 2020 and held it in 17 quarters. The position peaked at $60.7K in Q1 2021. 0 funds tracked by Wall St. Rank hold ONCT as of Q1 2025.
- Steward Partners Investment Advisory reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Steward Partners Investment Advisory sold 15 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $8.
- Steward Partners Investment Advisory first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 17 quarters.
- Steward Partners Investment Advisory's Oncternal Therapeutics, Inc. Common Stock position peaked at $60.7K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Steward Partners Investment Advisory's 13F filing for Q1 2025, filed 13 May 2025.